医学
心脏病学
心肌梗塞
内科学
置信区间
C反应蛋白
中性粒细胞与淋巴细胞比率
经皮冠状动脉介入治疗
冠状动脉疾病
射血分数
曲线下面积
淋巴细胞
心力衰竭
炎症
作者
Muhsin Kalyoncuoğlu,Gündüz Durmuş
出处
期刊:Coronary Artery Disease
[Ovid Technologies (Wolters Kluwer)]
日期:2020-03-01
卷期号:31 (2): 130-136
被引量:47
标识
DOI:10.1097/mca.0000000000000768
摘要
Background This study aimed to investigate the predictive value of the newly defined C-reactive protein (CRP)-toalbumin ratio (CAR) in determining the extent and severity of coronary artery disease (CAD) in comparison with the other inflammatory markers such as neutrophil-tolymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), in patients with non-ST-elevated myocardial infarction (NSTEMI). Patients and methods This study is retrospectively designed and includes 205 patients with NSTEMI with a mean age of 56.6± 11.4 years. The study cohort was subdivided into two groups according to Synergy Between Percutaneous Coronary Intervention with Taxus and cardiac surgery score (SS) as low (<23) and intermediate-high (≥23). Complete blood counts, serum CRP, and serum albumin were obtained at admission. The CAR, NLR, and PLR values of all patients were calculated. Then, we evaluated the relationship of CAR, NLR, and PLR with the CAD extent and severity. Results CAR and NLR were moderately correlated with SS ( r = 0.517, P < 0.001; r = 0.222, P = 0.001, respectively), whereas PLR showed weak correlation with SS ( r = 0.191, P = 0.006). According to multivariate analysis models, CAR, NLR, and left ventricular ejection fraction were found to be independent predictors of CAD severity ( P < 0.05). The area under the curve (AUC) for CAR (AUC: 0.829; 95% confidence interval: 0.770–0.878) was significantly greater than the AUC of NLR (AUC: 0.657; 95% confidence interval: 0.588–0.722), with P value of 0.002. A CAR more than 17 predicted an intermediate-high SS with 86% sensitivity and 76% specificity. Conclusion Novel inflammatory marker CAR can be used as a reliable marker in prediction of CAD severity in patients with NSTEMI.
科研通智能强力驱动
Strongly Powered by AbleSci AI